Skip to main content

Table 1 Patient characteristics for PSMA study

From: Muscarinic inhibition of salivary glands with glycopyrronium bromide does not reduce the uptake of PSMA-ligands or radioiodine

Patient Age (years) Height (cm) Weight (kg) TNM Initial Gleason score PSA (ng/ml)
1 68 182 90 T2N1M0 6 13.2
2 76 182 87 T0N1M0 (BCR) 7 1.4
3 82 174 97 T2N0M1 6 14.1
4 66 174 83 T2N0M0 8 7.7
5 75 181 80 T0N1M1 (BCR) 8 2.9
6 74 178 81 T + N0M0 (BCR) 7 3.1
7 64 175 77 T0N0M1 (BCR) 7 8.8
8 74 183 82 T3N0M0 7 19.0
9 72 174 68 T0N1M1 (BCR) 8 1.6
10 73 178 83 T0N0M1 (BCR) 9 0.4
  1. TNM = Clinical stage of prostate cancer, including findings on the baseline PSMA PET/CT; BCR = Biochemical recurrence; PSA = Prostate-specific antigen, measured prior to the baseline PSMA PET/CT